The Federal Circuit rejected more than a dozen of Novartis Pharma AG ‘s arguments why the appeals court should undo an administrative patent …
The Federal Circuit rejected more than a dozen of Novartis Pharma AG ‘s arguments why the appeals court should undo an administrative patent …